Supplementary Figure 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 25KB, Supplementary Figure S1. Patient disposition: AE, adverse event. KRAS, Kirsten rat sarcoma-2. PD, progressive disease. q2w, every 2 weeks. q3w, every 3 weeks.
Authors: Eric Angevin, Josep Tabernero, Elena Elez, Steven J. Cohen, Rastilav Bahleda, Jean-Luc van Laethem, Christian Ottensmeier, Jose A. Lopez-Martin, Sally Clive, Florence Joly, Isabelle Ray-Coquard, Luc Dirix, Jean-Pascal Machiels, Neil Steven, Manjula Reddy, Brett Hall, Thomas A. Puchalski, Rajesh Bandekar, Helgi van de Velde, Brenda Tromp, Jessica Vermeulen, Razelle Kurzrock
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361968657